Access cutting-edge glioblastoma treatment through this clinical trial at a research site in Washington Dc. Study-provided care at no cost to qualified participants.
Access glioblastoma specialists in Washington Dc at no cost
This study follows strict safety protocols and ethical guidelines
All study-related glioblastoma treatment provided free
This is a randomized, open-label, phase 2 study evaluating the safety and efficacy of oral ropidoxuridine as a radiation-sensitizing agent in patients with newly diagnosed wild-type isocitrate dehydrogenase glioblastoma with an unmethylated O6-methylguanine-DNA methyltransferase promoter, undergoing standard 60 Gy radiotherapy.
Sponsor: Shuttle Pharmaceuticals, Inc.
Check if you qualify for this glioblastoma clinical trial in Washington Dc, DC
If you're searching for glioblastoma treatment options in Washington Dc, DC, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Washington Dc research site is actively enrolling participants for this clinical trial. You'll receive care from experienced glioblastoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.